810 million women still not using mobile internet in low- and middle-income countries, compared to 595 million men

810 million women still not using mobile internet in low- and middle-income countries, compared to 595 million men

Persistent barriers related to affordability, skills and safety concerns continue to limit women's digital inclusion in low- and middle-income countries LONDON, June 10, 2026 /PRNewswire/ -- The gender gap in mobile internet adoption narrowed...

Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet

Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet

CHENGDU, China, May 31, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's trophoblast...

SynuSight-Shanghai Jiao Tong University Collaboration Published in Cell, Advancing Diagnostic Classification of Synucleinopathies

SynuSight-Shanghai Jiao Tong University Collaboration Published in Cell, Advancing Diagnostic Classification of Synucleinopathies

SHANGHAI, May 27, 2026 /PRNewswire/ -- SynuSight Biotech (SynuSight), a clinical-stage biotech company focused on innovative pipeline development for neurodegenerative diseases, today announced the publication of a collaborative study in Cell with...

Climate action key to affordable housing, but buildings decarbonisation stalls

Climate action key to affordable housing, but buildings decarbonisation stalls

NAIROBI, Kenya, May 19, 2026 /PRNewswire/ -- Decarbonisation of the buildings and construction sector has slowed, leaving it both a major emissions source and increasingly vulnerable to climate impacts and energy price shocks, according to a new...

Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026

Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026

HONG KONG, May 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be...

Hidden Muscle Fat Poses Danger to Heart, Metabolism

Hidden Muscle Fat Poses Danger to Heart, Metabolism

OAK BROOK, Ill., May 5, 2026 /PRNewswire/ -- Using a deep learning model to analyze the composition of large muscles on MRI, German researchers found that the proportions of intermuscular fat and lean muscle mass were associated with high blood...

Kingsoft Cloud Files Annual Report on Form 20-F for Fiscal Year 2025 and Releases 2025 Environmental, Social and Governance Report

Kingsoft Cloud Files Annual Report on Form 20-F for Fiscal Year 2025 and Releases 2025 Environmental, Social and Governance Report

BEIJING, April 23, 2026 /PRNewswire/ -- Kingsoft Cloud Holdings Limited ("we," "Kingsoft Cloud" or the "Company") (NASDAQ: KC and HKEX: 3896), a leading cloud service provider in China, today announced that it filed its annual report on Form 20-F...

Nature Reviews Drug Discovery | Target Identification and Assessment in the Era of AI

Nature Reviews Drug Discovery | Target Identification and Assessment in the Era of AI

CAMBRIDGE, Mass., April 22, 2026 /PRNewswire/ -- Target identification is the first and perhaps most critical step in drug discovery and development. Although the human genome contains roughly 20,000 protein-coding genes, only about 4,500 are...

Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine

Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine

SHANGHAI, April 22, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industrial chain, announced that a recent clinical case report on its self-developed novel Nectin-4 ADC (bulumtatug...

Nuance Pharma Announces Publication of Phase 3 ENHANCE-CHINA Data in the CHEST Journal

Nuance Pharma Announces Publication of Phase 3 ENHANCE-CHINA Data in the CHEST Journal

Ohtuvayre® (ensifentrine) helped improve lung function in Chinese adult patients in in data published in peer reviewed journal SHANGHAI, April 20, 2026 /PRNewswire/ -- Nuance Pharma ("Nuance" or the "Company") announces that CHEST, the official...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 12
  • menu
    menu